Slides
Page 1
Devyser Earnings call Q3 2025 November 5, 2025
Page 2
Jan Wahlström CEO Sabina Berlin CFO Theis Kipling CCO T oday’s presenters
Page 3
Jan Wahlström- New CEO
Page 4
4 Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth 16% Gross margin 75% EBIT 1.3 MSEK Cash position 85 MSEK 4 Third quarter financials
Page 5
5 Revenue • Sales 179 MSEK (153 MSEK) • Growth 17% Gross margin 81% EBIT -8 MSEK Cash position 85 MSEK 5 Financials Jan-Sept
Page 6
T urning around towards profitability · Re-organization deliversimproved profitability · Continued growth,supported by thelaunches of new products · Cost focus and continuous improvement Organization that is better balanced and efficient – without compromising growth
Page 7
Product launches in Q3 · A lot of our focus has been on the launches we did in June, HLA loss and Genomic blood typing. · Q3 is normally more soft on launches, but today we launched CFTR IVDR · We work on moving products from RUO and IVDD to IVDR
Page 8
More highlights · MolDx feedback · FDA path for Accept
Page 9
Third quarter 2025
Page 10
10 Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7% 10 Third quarter
Page 11
11 Rolling 12 months net sales
Page 12
12 Sales by region Q3 2025 Q3 2024 % of Q3 2025 % of Q3 2024 % Growth QoQ EMEA 51.7 45.2 91.8% 92.7% 14.4% Asia-Pacific 1.9 2.1 3.4% 4.2% -6.6% North and South America 2.7 1.5 4.8% 3.1% 87.0% Total 56.4 48.7 100.0% 100.0% 15.7%
Page 13
13 Sales by sales channel Q3 2025 Q3 2024 % of Q3 2025 % of Q3 2024 % Growth QoQ Direct sales 46.4 36.7 82.3% 75.2% 26.5% Distributor sales 10.0 12.1 17.7% 24.8% -17.3% Total 56.4 48.7 100.0% 100.0% 15.8%
Page 14
14 Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7% Gross margin 75.0% (72.3%) 14 Third quarter
Page 15
15 Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7% Gross margin 75.0% (72.3%) EBIT • 1.3 MSEK (-21.8) 15 Third quarter
Page 16
16 Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7% Gross margin 75.0% (72.3%) EBIT • 1.3 MSEK (-21.8) Strong financial position • 84.9 MSEK in liquidity • No debts 16 Third quarter
Page 17
Highlights Q3 and Commercial outlook
Page 18
Q3 commercial recap · A good quarter focused on getting HLA Loss and Genomic Blood Typing off the ramp · Lead generation YTD more than 3x doubled vs last year driving a strong growth in number of new customers · ASHI meeting generated a lot of interest in HLA Loss · North America continues to grow welland will continue to accelerate · Our European markets are growing as per plan YTD
Page 19
Update on Thermo Fisher Scientific Q3 wasslowdue to a strongQ2 ASHI conferencewassolid and wecontinueto gain tractiontogetherwith Thermo Fisher Orders from Thermo Fisher areexpectedto strenghtenin Q4 followingthe establishedpattern FDA program continueson plan
Page 20
North America update Devyser Genomic Laboratories Accept cfDNA feedback from MolDx was received with additional requests which we’re currently assessing Cyted collaboration is following plan –revenues and volumes to consistently increase following their succesful capital raise RHDtesting remains being a potential gamechanger for Devyser in the US. ~15% of americans are rh negative / 3.7m births annually means 550k patients to be tested yearly Devyser RHD was launched through Quest on August 25th. Additional potential partners have expressed interest Canadian blood services are now expected to go live on January 1 and Hema Quebec in Q3 2026 UNC are going live with CFTR testing end of this year
Page 21
• A quarter higher is Italy that grew 19% during Q3 which is very strong (excluding Chimerism) • Broadly across Europe we see continued upselling progress within existing accounts incl. University of Leuven where we're discussing a significant tender for CFTR NGS as described in one of the analyst reports • The demand for IVDR certified products increases which makes Devyser uniquely positioned due to our regulatory strength and ability to launch IVDR products even in the highest risk classes (Class C & D). • With CFTR NGS IVDR-certified we already have approx. +30% of our Class C&D products certified Europe
Page 22
22 Going forward • Execute on updated strategy – now delivering another positive EBIT quarter • Capitalize on our RnD efforts • Continue to work on organizational efficiency • Continue our path to profitability and positive cash flow 22
Page 23
23 Q&A 23
Page 24
Connect with us www.devyser.com Thank you!